bristol-myers squibb co (BMY) Key Developments
Bristol-Myers Squibb Company Announces Transfer of Full Commercialisation Rights to Eli Lilly and Company for Erbitux (Cetuximab)
Apr 17 15
Bristol-Myers Squibb Company declared an agreement to transfer the rights to Erbitux (cetuximab) in North America, including the US, Canada and Puerto Rico, to Eli Lilly and Company. The companies added the rights include, but are not limited to, full commercialisation and manufacturing operational responsibilities of Erbitux (cetuximab), an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of patients with certain advanced colorectal and head and neck cancers. Following a 14-year collaboration, Lilly's wholly-owned subsidiary ImClone and Bristol-Myers Squibb will work closely to ensure a smooth transition on Erbitux. Bristol-Myers Squibb will receive tiered royalties based on net product sales in North America after the completion of the transition through September 2018. This transition is expected to be completed in the fourth quarter of 2015.
Bristol-Myers Squibb Company and uniQure Collaborate to Develop New Cardiovascular Disease Therapies
Apr 15 15
Bristol-Myers Squibb Company and uniQure N.V. have signed a new agreement, under which BMS receives access for uniQure's gene therapy technology platform to develop new therapies for cardiovascular diseases. The collaboration includes uniQure's proprietary gene therapy program for congestive heart failure that is
intended to restore the heart's ability to synthesize S100A1, a calcium sensor and master regulator of heart function, and thereby improve clinical outcomes for patients with reduced ejection fraction. Beyond cardiovascular diseases, the agreement also includes the potential for target-exclusive collaboration in other disease areas. In total, the companies may collaborate on ten targets, including S100A1. uniQure will lead discovery efforts and be responsible for manufacturing of clinical and commercial supplies using its vector technologies and its industrial, proprietary insect-cell based manufacturing platform. Bristol-Myers Squibb will lead development and regulatory activities across all programs and be responsible for all R&D costs. Bristol-Myers Squibb will be solely responsible for commercialization of all products from the collaboration. This collaboration will accelerate the application of gene therapy for large patient populations suffering from heart diseases and will complement the further development of uniQure's internal pipeline in two focus areas: liver diseases, including hemophilia, and CNS, including lysosomal storage diseases.
Bristol-Myers Squibb Company, uniQure N.V. - Special Call
Apr 6 15
To discuss the collaboration with Bristol-Myers Squibb Company i.e. Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases
Bristol-Myers Squibb Company Announces the Agreement with UniQure N.v. to Develop Gene Therapies for Cardiovascular Diseases
Apr 6 15
Bristol-Myers Squibb Company announced that it will work with Dutch biotechnology company uniQure to develop gene therapies for cardiovascular diseases. The companies said uniQure is studying a drug that restores the heart's ability to synthesize a protein called S100A1. Bristol-Myers Squibb could pay uniQure $254 million if that drug is successfully developed and approved for sale, and it could pay up to $217 million for each additional drug. UniQure will also get payments based on sales targets and royalties on any approved drugs. The companies will choose a total of 10 therapeutic targets.
Bristol-Myers Squibb Mulls Acquisition Of Stakes In uniQure
Apr 6 15
Bristol-Myers Squibb Company (NYSE:BMY) is seeking acquisition of uniQure N.V.(NasdaqGS:QURE). Bristol-Myers will acquire an additional 5%in the Amsterdam-based company before December 31, 2015, at a 10% premium.